Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status

BACKGROUND AND AIMS: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. METHODS: Prespecified analysis of a non-interventional, prospective, real-world study in Germany. RESULTS: A total of 558 (49.5%) pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kallmann, Boris A., Ries, Stefan, Kullmann, Jennifer S., Quint, Laura M., Engelmann, Ulrich, Chan, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135216/
https://www.ncbi.nlm.nih.gov/pubmed/34046085
http://dx.doi.org/10.1177/17562864211005588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135216/
https://www.ncbi.nlm.nih.gov/pubmed/34046085
http://dx.doi.org/10.1177/17562864211005588

Ejemplares similares